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SUMMARY
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies. To investigate the
cellular origin(s) of this cancer, we determined the effect of PDAC-relevant gene mutations in distinct cell
types of the adult pancreas. We show that a subpopulation of Pdx1-expressing cells is susceptible to onco-
genic K-Ras-induced transformation without tissue injury, whereas insulin-expressing endocrine cells are
completely refractory to transformation under these conditions. However, chronic pancreatic injury can alter
their endocrine fate and allow them to serve as the cell of origin for exocrine neoplasia. These results suggest
that one mechanism by which inflammation and/or tissue damage can promote neoplasia is by altering the
fate of differentiated cells that are normally refractory to oncogenic stimulation.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer death in the United States (Li et al., 2004). Iden-
tification of the cell(s) of origin of PDAC and defining the
biochemical and biological changes that accompany their trans-
formation are essential for the development of early detection
and treatment tools.
The pancreas is composed of four parenchymal cell types:
acinar, ductal, centroacinar (exocrine), and islet (endocrine)
cells. The acinar cells synthesize and secrete zymogens into
the ductal lumen. The ducts carry the enzymes to the duodenum
and generate bicarbonate. The centroacinar cells (CACs) have
been suggested to be progenitor cells in the adult pancreas.
The islets of Langerhans are composed of endocrine cell types,
which secrete insulin and other proteins that regulate glucose
homeostasis (Bardeesy and DePinho, 2002). Rare cells express-Cing endocrine markers such as insulin can also be found associ-
ated with the acini and the ductal epithelium (Mills, 2007).
PDAC arises from in situ precursor lesions termed pancreatic
intraepithelial neoplasia (PanIN) (Hruban et al., 2001). PanIN
lesions include a spectrum of abnormal proliferative ductal struc-
tures (termed PanIN 1–3) that are recognized by transformation
from a cuboidal to columnar epithelium, mucin production, and
nuclear atypia.
Mutations that result in a constitutively active K-RAS are found
in over 95% of PDACs and are believed to be an initiating event
for this type of cancer (Jones et al., 2008; Rozenblum et al.,
1997). KRAS encodes a small GTPase that in its active GTP-
bound form promotes a wide range of cellular responses
including proliferation, survival, migration, and metabolism
(Shields et al., 2000). The CDKN2A locus encodes the Ink4A
and ARF tumor suppressor genes and is also frequently mutated
in PDAC. INK4A inactivation mutations are present in virtually allSIGNIFICANCE
The identification of the cell type(s) from which PDAC originates and is maintained is essential for the development of new
methods for PDAC diagnosis and treatment. In this paper, we demonstrate that oncogenic K-Ras can transform Pdx1-
expressing cells in the adult pancreas of the mouse in the absence of tissue injury. In contrast, insulin-expressing cells
require injury in combination with K-Ras activation for transformation. Our study emphasizes the role of both genetic and
nongenetic events in PDAC initiation and provides additional mouse models to aid in the development of new treatment
and diagnostic strategies.ancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier Inc. 379
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the malignant potential of mutant K-RAS. Other frequent alter-
ations include loss-of-function mutations of the SMAD4 and
p53 tumor suppressor genes (Jaffee et al., 2002). Moreover,
developmental regulatory pathways, in particular the Notch,
Sonic Hedgehog, and Wnt pathways, are often activated in
PDACs (Berman et al., 2003; Miyamoto et al., 2003; Thayer
et al., 2003; Wang et al., 2009).
PDAC is commonly believed to arise from transformation of
ductal cells, although experimental studies have suggested
other differentiated cells or progenitor/stem cells as potential
origin(s) for this type of cancer. For instance, mouse models ex-
pressing various oncogenes in acinar cells during development,
such as the Elastase-Tgfa (Wagner et al., 1998) and Elastase-
KrasG12D (Grippo et al., 2003) transgenic strains and the knockin
Mist1-Kras4BG12D animals (Tuveson et al., 2006), have impli-
cated acinar cells as being susceptible to transformation and
giving rise to tumors containing ductal elements. Transplantation
of mouse islet cell cultures expressing the polyoma virus middle
T oncogene into histocompatible mice resulted in the induction
of pancreatic cancer with ductal histology (Yoshida and Hana-
han, 1994), suggesting a potential endocrine origin for PDAC.
A role of CACs has been proposed based on studies of mice
that harbor a pancreas-specific deletion of the PTEN gene; these
animals exhibit a proliferative expansion of CACs that can
progress to carcinoma (Stanger et al., 2005). Nestin+ exocrine
progenitor cells have been shown to be highly responsive to
K-Ras oncogenic activation and were suggested to represent
a progenitor origin for PDAC (Carriere et al., 2007).
The close developmental relationships of the different pancre-
atic cell types and the capacity of endodermal lineages to trans-
differentiate (Slack, 1995) add complexity to the PDAC cell-of-
origin question. PanIN lesions can express markers of gastric
and foregut differentiation (Prasad et al., 2005), suggesting that
some degree of transdifferentiation occurs routinely during
PDAC progression. This developmental plasticity is evident in
some human PDACs that show focal expression of nonductal
lineage markers, including endocrine and exocrine factors.
More recently, Habbe et al. (2008) and De La O et al. (2008)
have shown that activation of oncogenic K-Ras in acinar cells
of the adult mouse leads to efficient mPanIN formation. These
groups have also demonstrated in vivo acinar-to-ductal transdif-
ferentiation by lineage tracing studies in these models (De La O
et al., 2008; Habbe et al., 2008). Given this plasticity, it is possible
that there is no exclusive cell of origin for PDAC and that specific
genetic alteration(s) define the resulting malignant phenotype
regardless of the cell in which they occur. Moreover, the physio-
logical context, including tissue damage and inflammation, may
alter a given cell’s susceptibility to transformation. For example,
Guerra et al. (2007) have reported that K-Ras activation in acinar
cells (using the K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre system)
resulted in adult onset malignancy only following treatment
with caerulein, which causes tissue injury and inflammation
(Guerra et al., 2007).
In this study, we investigate whether PDAC arises from an
exclusive cell of origin and whether a combination of genetic
and nongenetic events can collaborate to induce neoplasia in
a range of cell types. We describe the use of genetic manipula-
tion of the mouse to systematically determine the effects of380 Cancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier Inconcogenic K-Ras in distinct subsets of pancreatic cells of the
adult mouse in a context-dependent manner.
RESULTS
Temporally Restricted Activation of Oncogenic K-Ras
in Distinct Cell Populations of the Adult Pancreas
Activation of oncogenic K-Ras in the common pancreatic embry-
onic progenitor in the Pdx1Cre;LSL-KrasG12D model results in
mPanIN formation and spontaneous progression to PDAC
(Aguirre et al., 2003; Hingorani et al., 2003). Because human
PDAC is an adult-onset malignancy, we sought to engineer
PDAC mouse models in which oncogenic K-Ras (KrasG12D) is
activated in the adult animal. We crossed the LSL-KrasG12D
strain to different cell-specific CreER lines and compared the
phenotypic effect of KrasG12D activation on these distinct cell
populations in the adult pancreas (Figure 1A). The CreER lines
used were: (1) the Pdx1CreERTM transgenic strain (Gu et al.,
2002), which marks the earliest pancreatic progenitor cell during
development as well as adult endocrine b cells, some ductal,
acinar cells, and possibly adult progenitor/stem cells (Koizumi
et al., 2003; Stoffers et al., 1999; Swift et al., 1998; Wu et al.,
1997); (2) the RipCreERTM transgenic strain (Dor et al., 2004),
which is selective for insulin+ cells; and (3) the acinar procarboxy-
peptidase A1 CreERT2 (proCPA1CreERT2) knockin strain (Zhou
et al., 2007). The recombination specificity and efficiency of the
different CreER strains was determined by crossing them to
the LSL-LacZ reporter mouse and analyzing the X-gal-stained
pancreata of their Tamoxifen (TM)-treated compound progeny
(Figures 1B–1E and Table S1 available online). As shown in
Figure 1B, in the Pdx1CreERTM transgenic strain, recombination
was achieved in a mosaic fashion in the islets, acinar, and ductal
cells. The proCPA1CreERT2 strain exhibited recombination
mainly in acinar cells and possibly CACs; however, recombina-
tion was evident also in a subset of ductal and islet cells. Recom-
bination in this strain was variable, with half of the treated mice
showing no evidence of recombination and the other half ranging
from 0% to 49% in acinar cells (Figure 1C, Table S1, and data not
shown). With TM administration, the RipCreERTM transgenic
strain was very specific and efficient in causing recombination
in both insulin-producing b cells located in the islets of Langer-
hans and in single insulin+ cells found scattered throughout the
pancreas parenchyma, as shown by X-gal and coimmunofluor-
escent (CoIF) staining (Figures 1D and 1E, respectively, and
Table S1).
Expression of KrasG12D in different cell types of the adult
pancreas was achieved by systemic TM administration in mice
at 14–56 days of age. Because newly transformed cells would
be expected to resemble their cell of origin both genetically
and morphologically, we sought to define the earliest time point
when transformed cells could be detected after TM administra-
tion. Therefore, mice were sacrificed at different times following
the last dose, ranging from 4 to 240 days.
KrasG12D Induces Transformation in Pdx1+ Cells
of the Adult Pancreas
Pdx1CreERTM;LSL-KrasG12D mice were treated with TM at day
14, 21, 24, 27, or 56 after birth and sacrificed after 4–120 days.
mPanINs and ductal metaplasia were observed in all age groups.
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most prevalent and were observed to a comparable extent
across the three main age groups, whereas mPanIN 1B were
less frequent in the 56-day-old group. Although mPanIN lesions
were predominantly grade 1, grade 2 lesions were also identified,
mostly at 120 days after TM administration and only in the
14- and 27-day-old treated mice (Table S2 and Figure 2E). These
results suggest that the Pdx1+ target cell for transformation is
either less susceptible or less abundant in 56-day-old mice.
mPanIN 3 was found only in one mouse that was analyzed
188 days after TM administration, and it was also the only mouse
that developed PDAC. This result is consistent with observations
in humans that it is unusual to find PanIN 3 in pancreata lacking
invasive carcinoma (Mills, 2007).
TM-treated 14- or 27-day-old mice exhibited additional
phenotypes (n = 23). One of the most notable was the appear-
ance of acinar cells and ductal structures ‘‘embedded’’ in the
islets of Langerhans as soon as 10 days after TM treatment
(Figures 3A and 3B, respectively). The ductal structures grew
over time (Figure 3C) and remained proliferative (data not
shown). These lesions became elongated and produced mucin,
reminiscent of mPanINs (Figure 3D). In contrast, some mPanIN in
the exocrine compartment harbored cells that positively stained
for endocrine markers such as glucagon, insulin, somatostatin,
and PYY (Figures S1A and S1B and data not shown). Other histo-
logic findings at 120 days after TM treatment included robust
atrophy of the pancreas with a hypoplastic exocrine compart-
ment, large cystically dilated areas, and strong stromal reaction
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Figure 1. KrasG12DActivation in Distinct Cell Populations of theAdult
Pancreas
(A) Diagram describing the different mouse strains used in the study. The LSL
KrasG12D strain was crossed to the insulin+ cell specific RipCreERTM strain
(Dor et al., 2004); to the acinar proCPA1CreERT2 strain (Zhou et al., 2007);
and to the putative stem/progenitor cell specific Pdx1CreERTM strain (Gu
et al., 2002).
(B D) X gal stained pancreata of TM treated Pdx1CreERTM;LSL LacZ (B),
proCPA1CreERT2;LSL LacZ (C), and RipCreERTM;LSL LacZ (D). Note specific
recombination in islet (indicated by black arrow), acinar (indicated by an
orange arrow), and ductal (indicated by a red arrow) cells (B); in acinar cells
(C) and a duct (C, indicated by an arrow); and in the islets of Langerhans (D)
and scattered extrainsular endocrine cells (D, indicated by an arrow).
(E) LacZ and insulin CoIF staining of pancreas derived from a TM treated
RipCreERTM;LSL LacZ. Note double staining of a single cell (top row) and of
cells within the islets of Langerhans (lower row). (Ea) and (Ed) show insulin
staining; (Eb) and (Ee) show LacZ staining; and (Ec) and (Ef) show a merge.
Scale bars represent100 mm.
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Figure 2. KrasG12D Activation by Pdx1CreERTM Causes mPanIN
Formation and Ductal Metaplasia
(A D) H&E stained sections of Pdx1CreERTM;LSL KrasG12D mice 20 (A) and
120 (B D) days after TM administration.
(A) mPanIN1A (black arrow). Note flat columnar epithelium with mucin accu
mulation and basally oriented nuclei (red arrow indicates ductal metaplasia).
(B) mPanIN1B. Note papillary architecture with small, basally oriented nuclei.
(C) mPanIN2. Note papillary architecture, moderate nuclear pleomorphism,
and partial loss of polarity.
(D) Ductal metaplasia. The scale bar represents 100 mm.
(E) Percentage of mice that developed different grades of mPanINs upon
KrasG12D activation at the described postnatal dates.Cancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier Inc. 381
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treated mice (n = 15) (Table S2). These results exclude the possi-
bility of leaky Cre recombinase activity and TM-independent
K-Ras activation during development and/or adulthood. In
addition, we observed no evidence of chronic pancreatitis in
treated mice. Since TM is dissolved in corn oil, which by itself
causes a mild form of peritonitis (Figure S1E), we treated
Pdx1CreERTM;LSL-KrasG12D mice with TM dissolved in carbox-
ymethyl cellulose (CMC) by oral gavage. Dissolving TM in corn
oil or CMC did not affect the specificity and efficiency of
Cre-induced recombination as confirmed by X-gal staining in
mice harboring a LacZ reporter (data not shown). As shown
in Figure S1F, pancreata of mice treated with TM dissolved in
CMC were free of peritonitis yet still developed grade 1 mPanINs
(n = 5). This result precludes the possibility that the corn oil-
induced peritonitis was essential for formation of mPanINs and
ductal metaplasia in the Pdx1CreERTM;LSL-KrasG12D model.
Activation of KrasG12D in combination with mutations of Ink4A/
Arf (Aguirre et al., 2003) or Trp53 (Jonkers et al., 2001) in Pdx1+
cells in the adult mouse resulted in formation of moderately to
poorly differentiated PDAC in 10/13 mice tested (Figure 4 and
Table S2). Many of the tumors contained undifferentiated areas
with sarcomatoid or anaplastic features, and extension beyond
the pancreas was common. We observed direct invasion into
the stomach and small intestine as well as metastasis to medias-
tinal lymph nodes, diaphragm, and peritoneal adipose tissue
(Figure 4 and data not shown). We also identified a full range of
mPanIN lesions in these mice, including grade 3 (Table S2 and
Figures 4A and 4B). Thus,Pdx1+ cells, or at least a subpopulation
of Pdx1+ cells, represent an excellent candidate to be the/a cell
of origin for PDAC in the mouse and in humans.
Targeted Expression of KrasG12D in proCPA1+ Cells
Targeting the expression of KrasG12D to pancreatic acinar cells
and other cell types by treating proCPA1CreERT2;LSL-KrasG12D
mice with TM resulted in low grade mPanIN-1A formation in only
2/20 mice (Table S3 and Figure S2A). All mice were tested and
confirmed for LSL-KrasG12D recombination by PCR analysis of
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Figure 3. KrasG12D Activation by Pdx1CreERTM Causes Intraislet
Ductal/Acinar Lesions
(A D) H&E stained sections of Pdx1CreERTM;LSL KrasG12D mice 10 (A and B),
20 (C), and 40 (D) days after TM administration. Acinar cells (A, indicated by an
arrow) and small ducts (B, indicated by an arrow) embedded within the islets
are shown. Enlarged ducts within the islets (C, indicated by an arrow) are
shown. Mucin producing elongated cells in ductal structures in the islets (D,
indicated by an arrow) are shown. The scale bar represents 50 mm.
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Figure 4. KrasG12D Activation in Combination with p53 or Ink4A/Arf
loss in Pdx1+ Cells of the Adult Pancreas Results in mPanIN3 and
PDAC Development
(A E and G H) H&E stained sections of mPanIN3 and PDACs derived from
Pdx1CreERTM;LSL KrasG12D;Trp53flox/flox mice.
(A and B) mPanIN3 lesions. Note adjacent tumor (t) and high grade features,
including cribriform architecture (A) and apical mitosis (B). Arrows point to
mitotic figures.
(C and D) Invasive, moderately differentiated PDAC (note invasion through the
duodenal wall [d] in [C]).
(D) Enlarged box in (C).
(E) Undifferentiated PDAC. Tumor (t) invades submucosa of the small intestine
and abuts intestinal epithelium (ie).
(F) H&E stained section of undifferentiated PDAC (t) and residual normal acini
(a) derived from a Pdx1CreERTM;LSL KrasG12D;Ink4A/Arf flox/flox mouse.
(G and H) Metastatic PDAC.
(G) Metastasis (m) to mediastinal lymph node (ln) with adjacent lung (lu).
(H) Metastasis to diaphragm (d). The scale bars represent 100 mm in (A) and (B);
200 mm in (C); 50 mm in (D) and (F); and 200 mm (E), (G), and (H).382 Cancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier Inc.
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suggest that proCPA1+ cells are not efficiently transformed by
KrasG12D into mPanIN lesions in the adult mouse. It has been
recently shown that KrasG12D activation in acinar cells of the
adult mouse leads to efficient mPanIN formation in the absence
of tissue injury in the Ela-CreERT2Tg/+, Mist1CreERT2/+, and
ElaCreERT strains (De La O et al., 2008; Habbe et al., 2008).
The phenotypic diversity observed between these models is
discussed below (see also Table S7).
To determine whether loss of p53 or Ink4A/Arf could affect the
neoplastic potential of proCPA1+ cells, we combined the LSL-
KrasG12D allele with the Trp53flox or Ink4A/Arf flox alleles on the
background of the proCPA1CreERT2 strain. The pancreata
derived from TM-treated proCPA1CreERT2;LSL-KrasG12D;Ink4A/
Arf flox/flox mice (n = 7) showed no overt cancer phenotype when
examined at 50, 83, 113, 158, 188, and 309 days after TM
administration. However, one proCPA1CreERT2;LSL-KrasG12D;
Trp53flox/flox mouse (n = 5) developed a moderately to poorly
differentiated PDAC 81 days after TM injection at 53 days of
age. The tumor contained undifferentiated areas, was locally inva-
sive, and metastasized to the liver and diaphragm (Table S3 and
Figure S2B). As described earlier, all mice in this study were
analyzed for DNA recombination by PCR (Table S3). We conclude
that highly aggressive PDAC can be initiated in proCPA1+ cells in
adult mice without chronic pancreatitis, albeit with low pene-
trance in this system.
In a previous study, Guerra et al. (2007) reported that selective
expression of an endogenous K-Ras(G12V) oncogene in adult cells
of the acinar/centroacinar lineage using the K-Ras+/LSLG12Vgeo;
Elas-tTA/tetO-Cremouse model resulted in no phenotype unless
the mice were pretreated with caerulein (Guerra et al., 2007).
Caerulein induces chronic pancreatitis that results in regenera-
tion of normal tissue and formation of metaplastic lesions of
a ductal phenotype in the exocrine compartment (Strobel et al.,
2007). The authors concluded that chronic pancreatitis can be
a cofactor in the induction of PDAC by the K-Ras(G12V) oncogene
in adult mice (Guerra et al., 2007). Because theproCPA1CreERT2;
LSL-KrasG12D mice described above were largely refractory to
KrasG12D-induced transformation, we set out to test whether
chronic pancreatitis could facilitate PDAC formation in these
mice.
Wetreated34- to60-day-oldmice (n=9)withcaerulein fora total
of 44–193 days. One month after caerulein treatment initiation, the
mice were treated with TM to activate Cre. In addition to caerulein-
induced inflammation and ductal metaplasia, 3/9 proCPA1
CreERT2;LSL-KrasG12D and proCPA1CreERT2;LSL-KrasG12D;
LSL-LacZ mice developed grade 1 mPanINs (Figure 5A and
Table S4). We confirmed LSL-KrasG12D recombination by
PCR analysis of DNA extracted from laser-captured microdis-
sected (LCM) lesions (Figure 5C and Table S4). Hence, the
mPanINs arose from ProCPA+ cells. Importantly, three out
of six proCPA1CreERT2;LSL-KrasG12D;p53flox/flox developed
PDAC when treated first with caerulein and then with TM
(Figure S3B and Table S4). mPanIN grades 1 and 2 were
observed, and the neoplastic lesions and advanced tumors
were similar to those arising in Pdx1CreERTM compound
mutant mice with respect to histologic appearance, local
invasion, and distant metastasis. In addition, a single proC-
PACreERtT2;LSL-KrasG12D;Ink4A/Arf f/f mouse that was treatedCfirst with TM and then with caerulein developed PDAC (Fig-
ure S3C and Table S4). To rule out false-positive results
due to nonspecific Cre recombinase activity upon caerulein-
induced injury, we treated proCPACreERT2;LSL-KrasG12D;
LSL-LacZ mice (n = 3) with caerulein without prior TM
administration for 8, 15, and 22 days. LacZ+ cells were not
observed in these mice (data not shown). Thus, the proCPA
CreERT2 allele remains tightly controlled under chronic
pancreatitis conditions. Immunofluorescence (IF) for CPA
revealed that most mPanIN cells in the proCPA1CreERT2;
LSL-KrasG12D mouse model failed to express this marker
(Figure 6D). This result supports the hypothesis that proCPA+
cells can undergo injury-induced transdifferentiation and give
rise to mPanIN formation in the context of KrasG12D activa-
tion. In addition, our results provide evidence that pancreatic
injury synergizes with KrasG12D in transforming proCPA+ cells
and initiating PDAC.
Targeted Expression of KrasG12D in insulin+ Cells
Targeting the expression of KrasG12D to insulin+ cells by treating
RipCreERTM;LSL-KrasG12D mice with TM did not result in mPa-
nIN formation in any of the different age groups (n = 30), even
after 8 months (Table S3). Although these results suggest that
insulin+ cells are not targeted for transformation by KrasG12D,
we nonetheless combined the KrasG12D allele with the condi-
tional Trp53 or Ink4A/Arf alleles on the background of the
RipCreERTM strain. None of the RipCreERTM;LSL-KrasG12D;
Trp53flox/flox mice or the RipCreERTM;LSL-KrasG12D;Ink4A/
Arf flox/flox mice developed mPanINs or PDAC (n = 14). As
described above, recombination of LSL-KrasG12D was confirmed
by PCR analysis of DNA extracted from tissue sections of all TM-
treated mice in this study (Table S3). These results strongly
suggest that insulin+ cells are highly refractory to transformation
by multiple oncogenic mutations.
We next set out to test the effect of chronic pancreatitis on
PDAC formation in the RipCreERTM;LSL-KrasG12D mice. Two
RipCreERTM;LSL-KrasG12D;LSL-LacZ mice were treated with
caerulein for a total of 84 and 89 days. One month after caerulein
treatment initiation, the mice were treated with TM to activate
Cre. Interestingly, grade 1 mPanINs were detected in one of these
mice (Figure 5B and Table S4). We confirmed LSL-KrasG12D
recombination in the pancreas of the mouse that did not show
mPanIN formation as well as in mPanINs derived from the second
mouse by PCR analysis of DNA extracted from tissue section and
of DNA extracted from LCM lesions, respectively (Figure 5C and
Table S4). Hence, the mPanINs observed arose from cells in
which the transgenic rat insulin promoter was active. Importantly,
all three RipCreERTM;LSL-KrasG12D;p53 flox/flox;LSL-LacZ mice
developed poorly and undifferentiated PDAC (n = 2 and n = 1,
respectively) when treated first with caerulein and then with TM
(Figure S3D and Table S4). As in the Pdx1CreERTM;LSL-
KrasG12D;p53 flox/flox mutant mice, these were highly aggressive
tumors that exhibited a capacity for local invasion and distant
metastasis.
One interpretation of these results (as well as those of Guerra
et al. [2007]) is that caerulein treatment or inflammation caused
a change in differentiated cells that made them susceptible to
K-Ras activation. To investigate this possibility, we crossed the
RipCreERTM;LSL-KrasG12D mice to the LacZ reporter strain andancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier Inc. 383
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days prior to caerulein treatment initiation (n = 6) (Table S4). In
this way, differentiated insulin+ cells and their progeny would
be marked by the LacZ expression and their fate could be iden-
tified after caerulein treatment by X-gal staining (Figure 5D).
Strikingly, LacZ+ mPanINs were found in 4/6 pancreata of these
mice (Figure 6A and Table S4). In the remaining two mice mPa-
nINs were not observed, which might be explained by the small
pancreatic area analyzed (less than 2 mm2; Table S6). In addi-
tion, two mice developed LacZ+ poorly to undifferentiated
tumors with local invasion to adjacent tissues. These results
suggest that KrasG12D-expressing insulin+ cells can be trans-
formed and give rise to mPanINs and PDAC specifically in the
context of chronic pancreatitis.
To explore the possibility of nonspecific Cre recombinase
activity upon caerulein-induced injury, we treated RipCreERTM;
LSL-KrasG12D;LSL-LacZ mice (n = 5) with caerulein without prior
TM administration. Surprisingly, despite the absence of TM,
LacZ+ cells were observed in the islets of Langerhans and in
scattered cells throughout the parenchyma as early as 2 days
after caerulein treatment initiation (data not shown). Thus,
although the RipCreERTM strain is tightly controlled and does
not normally show leaky expression of the Rat insulin promoter
in insulin cells or TM-independent activation of Cre recombi-
nase (Table S1), Cre activity was more promiscuous under
chronic pancreatitis conditions. This result raised the possibility
that the mPanIN lesions observed in the experiment described
above arose in non-insulin-expressing cells following inappro-
priate Cre activation during the caerulein treatment. To address
this possibility directly, we treated RipCreERTM;LSL-LacZ mice
(n = 5) with TM for 5–7 days, treated them with caerulein for
65 days, and subsequently analyzed them for coexpression of
LacZ and insulin by CoIF (Table S5). In all cases, LacZ+insulin+
cells were observed within the islet of Langerhans. In addition,
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Figure 5. Chronic Pancreatitis Promotes mPanIN Formation in Mouse Models Largely Refractory to KrasG12D Activation Alone
(A and B) H&E staining of pancreata derived from caerulein/TM treated proCPA1CreERT2;LSL KrasG12D (A) and RipCreERTM;LSL KrasG12D mice (B). Note
mPanIN formation (arrows). The scale bar represents 50 mm.
(C) PCR of tail (T) and laser captured microdissected mPanINs DNA from caerulein/TM treated proCPA1CreERT2;LSL KrasG12D (P1) and RipCreERTM;
LSL KrasG12D (P2) mice. The recombined allele (1lox) is present in the mPanINs DNA but not in the tail DNA of compound mutant mice.
(D) Suggested model of caerulein/inflammation induced mPanIN formation in TM treated RipCreERTM;LSL KrasG12D;LSL LacZ mice. TM administration results
in recombination induced activation of KrasG12D and LacZ expression in insulin+ cells of the adult mouse. This recombination is permanent and marks both the
cells and their progeny. Upon caerulein treatments, if insulin+ cells are targeted for transformation by KrasG12D, they will give rise to LacZ+ mPanINs. Otherwise,
only LacZ caerulein induced metaplasia will form. The scale bar represents 50 mm in (A) and (B) and represents 100 mm in (D).384 Cancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier Inc.
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cells scattered throughout the pancreata. We then calculated the
frequency of mPanIN lesions per mm2 in the TM/caerulein-
treated RipCreERTM;LSL-KrasG12D;LSL-LacZ and RipCreERTM;
LSL-KrasG12D mice. Importantly, the frequency of mPanIN
lesions in these mice was 6-fold higher than the frequency of
LacZ+insulin cells in TM/caerulein-treated RipCreERTM;LSL-
LacZ mice (p = 0.04 by Wilcoxon Rank Sum Test) (Tables S5
and S6). Thus, a minority of the mPanINs observed in the TM-
and caerulein-treated RipCreERTM;LSL-KrasG12D;LSL-LacZ and
RipCreERTM;LSL-KrasG12D mice might have arisen from insulin
cells. However, based on this statistical analysis, it is likely that
the vast majority of the mPanINs can be attributed to transfor-
mation of insulin+ cells. Thus, our results provide evidence
that insulin+ cells can be made susceptible to KrasG12D and
give rise to mPanIN and PDAC formation following tissue injury
and inflammation. Interestingly, immunohistochemistry (IHC)
revealed that most mPanIN cells in this model failed to express
insulin (Figures 6B and 6C). Although the mechanism through
which mature insulin-producing cells undergo this fate change
is unclear, it is notable that these mPanINs harbored Pdx1+ cells
and cells that positively stain for the Notch intracellular domain
(Figure 6E and data not shown).
To further study transformation of insulin+ cells, we treated
four RipCreERTM;LSL-KrasG12D;p53flox/flox;LSL-LacZ mice with
TM and 14–40 days later with caerulein for additional 42–52
days. These mice developed high-grade mPanIN and poorly
differentiated to undifferentiated carcinoma capable of local
invasion and distant metastasis (Figures 7A and 7B and Table
S4). The undifferentiated areas were morphologically identical
to those observed in Pdx1CreERTM;LSL-KrasG12D;Trp53flox/flox
mice and also resembled human undifferentiated pancreatic
carcinoma (Hoorens et al., 1998). Tumors in these mice were
negative for insulin as well as the neuroendocrine marker synap-
tophysin by IHC (Figures 7C and 7D). Furthermore, no preneo-
plastic lesions were observed in the islets of these mice (data
not shown). In conclusion, our results provide evidence that in
combination with pancreatic injury, KrasG12D-expressing insulin+
cells of the endocrine lineage, which are refractory to transfor-
mation under normal conditions, can also serve as a cell of origin
of PDAC, a malignancy with an exocrine phenotype.
DISCUSSION
We have studied the susceptibility of adult pancreatic cells to
transformation by KrasG12D. We show that Pdx1+ cells can effi-
ciently give rise to mPanIN and ductal metaplasia and, in combi-
nation with p53 or Ink4A/Arf deletion, can develop into PDAC. In
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Figure 6. Characterization of mPanINs Derived from TM and then
Caerulein Treated proCPA1CreERT2;LSL KrasG12D and RipCreERTM;
LSL KrasG12D Mice
(A C and E) X gal (A), insulin (B and C), and Pdx1 (E) staining of pancreata
derived from RipCreERTM;LSL LacZ;LSL KrasG12D mice. Note X gal (A) and
Pdx1 (E, indicated by black arrows) positive staining in mPanINs and negative
staining for insulin in most mPanINs (B and C).
(D and F) IF staining for CPA1 and IHC staining for Pdx1 of pancreata derived
from proCPA1CreERT2;LSL KrasG12D mice. Note positive and negative CPA1
staining in the same mPanIN (D, white arrows) and positive staining for Pdx1
(F, black arrows). Bars: A and B, 100 mm; C F, 100 mm.
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Figure 7. KrasG12D Activation and p53 Loss Followed by Chronic
Pancreatitis Results in mPanIN2 3 and PDAC Development from
Insulin+ Cells
Pancreata derived from RipCreERTM;LSL KrasG12D;Trp53flox/flox mice treated
with TM followed by caerulein.
(A) Multiple mPanINs (grade 2 and 3 [black and red arrows, respectively]) and
undifferentiated carcinoma (t). The arrowhead indicates a giant cell of invasive
carcinoma.
(B) Metastatic carcinoma in the diaphragm.
(C) Negative immunostain for insulin in carcinoma. The inset shows a positive
insulin immunostain in nonneoplastic islet.
(D) Negative immunostain for synaptophysin in carcinoma. Note positive stain
ing in axon located in the smooth muscle of the small intestine (arrow). The
scale bar for (A) (D) represent 400 mm.Cancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier Inc. 385
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insulin+ cells (which also express Pdx1) did not show any overt
phenotype, even in the context of tumor suppressor gene muta-
tion. Likewise, proCPA1+ cells were inefficiently transformed.
Thus, we conclude that under noninflammatory conditions,
a subpopulation of Pdx1+ cells of the adult pancreas have
heightened sensitivity to the KrasG12D oncogenic effects and
represent a cell of origin of PDAC. Of note, Habbe et al. (2008)
have reported that Pdx1+ cells are relatively resistant to
KrasG12D-induced transformation in 42-day-old mice. Our data
suggest that younger mice are more susceptible to transforma-
tion of this cell type. It is also possible that the different observa-
tions are attributable to background differences between the
mice used in both studies.
Four Cre lines have been used to target the expression of on-
cogenic K-Ras to adult acinar cells: K-Ras+/LSLG12Vgeo(KRasG12V);
Elas-tTA/tetO-Cre (Guerra et al., 2007); Ela-CreERT2Tg/+
and Mist1CreERT2/+ (Habbe et al., 2008); ElaCreERT (De La O
et al., 2008); and the proCPA1CreERT2 studied here. Different
phenotypes, ranging from no lesion to high-grade mPanIN-3
formation, were observed in these strains (Table S7). The pheno-
typic diversity might be explained by several factors, including:
(1) the K-Ras+/LSLG12Vgeo strain lacks the 30 UTR element, which
contains several regulatory sequences, including binding sites
for the let-7 miRNA family that regulates both N-Ras and
K-Ras (Johnson et al., 2005), and has been suggested to func-
tion in tumor suppression (Lee and Dutta, 2007; Mayr et al.,
2007; Takamizawa et al., 2004; Yu et al., 2007). Thus, the more
abundant lesion formation in the 10-day-old K-Ras+/LSLG12Vgeo;
Elas-tTA/tetO-Cre mice compared to the proCPA1CreERT2;
LSL-KrasG12D may result from more tightly controlled transla-
tional repression of KrasG12D versus K-Ras(G12V). (2) The models
utilize distinct K-ras activating mutations (G12V versus G12D),
which might have an effect on the oncogenic potency of K-Ras
(Bardeesy and Sharpless, 2006; Collado et al., 2005; Seeburg
et al., 1984). (3) Recombination efficiency differences between
the different strains may exist, either because of differences
between Cre-driving promoters, per se, mouse background, or
different TM and doxycycline administration protocols. (4) The
different mouse models may reflect a previously uncharacterized
heterogeneity of acinar cells with respect to function and/or
susceptibility to transformation. Nevertheless, the collective
observations provide evidence that there are acinar cells in the
adult pancreas sensitive to oncogenic K-Ras activation that
can progress to at least mPanIN in the absence of overt tissue
injury and that highly aggressive PDAC can be initiated from
proCPA1+ cells, albeit with low penetrance.
When injury was induced before recombination, the proCPA1
CreERT2;LSL-KrasG12D and RipCreERTM;LSL-KrasG12D mice
became sensitive to KrasG12D activation. Importantly, when we
activated KrasG12D first and then induced chronic pancreatitis,
RipCreERTM;LSL-KrasG12D mice still developed mPanINs. We
found that under caerulein-only treatment conditions Cre recom-
binase activity was not detectable in the proCPA1CreERT2
strain, although, surprisingly, it could be detected in insulin+
and rare insulin cells in the RipCreERTM strain. This result might
reflect a differential sensitivity to caerulein of CreERT2 (Indra
et al., 1999) in the proCPA1CreERT2 versus CreERTM (Danielian
et al., 1998) in the RipCreERTM strain. Alternatively, an increased386 Cancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier Incamount of Cre protein might be produced by the RipCreERTM
transgene in comparison with the proCPA1CreERT2 knockin
strain that might result in its greater sensitivity to caerulein.
Regardless of the effects of caerulein, the vast majority of the
mPanINs can be attributed to transformation of insulin+ cells,
although it is possible that a few mPanINs are derived from
insulin cells as well. Furthermore, 2/6 of the RipCreERTM;
LSL-KrasG12D;LSL-LacZ and all RipCreERTM;LSL-KrasG12D;
p53 flox/flox;LSL-LacZ mice (n = 4) developed high-grade mPanIN
and tumors that resembled the most aggressive PDAC that
arose in Pdx1CreERTM and proCPA1CreERT2 compound mice.
These tumors exhibited no morphologic or immunohistochem-
ical evidence of neuroendocrine differentiation. In addition, the
preinvasive changes in these mice were of an exocrine pheno-
type (i.e., mPanIN) rather than endocrine. Taken together, these
results show that insulin+ cells of the endocrine lineage of the
adult pancreas can transdifferentiate and give rise to highly
aggressive exocrine neoplasia (PDAC). Of note, LacZ+ cells
were not detected in ductal metaplasia in caerulein/TM-treated
RipCreERTM;LSL-LacZ mice (data not shown), suggesting that
the transdifferentiation of the insulin+ cells requires both injury
and oncogenic K-Ras. Similar results were observed by Strobel
et al. (2007) in RipCreERTM;Z/AP mice. Interestingly, oncogenic
K-Ras activation is rarely observed in human endocrine tumors
(Jonkers et al., 2007). This may in part be explained by reprog-
ramming of endocrine cells to an exocrine fate upon injury and
K-Ras activation.
The transdifferentiated cells in the RipCreERTM;LSL-KrasG12D
mice may be insulin+ cells that reside either in and/or outside
the islets of Langerhans. The physiological role of the insulin+
cells that reside outside of the islets is largely unknown.
However, the mPanINs in the caerulein/TM-treated mice were
always observed outside the islets, suggesting that these cells
may be more susceptible to KrasG12D than those that reside in
the islets. Interestingly, neoplastic ducts were found within the
islets of TM-treated Pdx1CreERTM;LSL-KrasG12D mice but not
when KrasG12D was activated during development with the non-
conditional Pdx1Cre strain (Hingorani et al., 2003). This may
reflect a developmental compensation mechanism or result
from mouse background differences.
Caerulein might promote KrasG12D-induced transformation by
several mechanisms. It is possible that a rare population of
proCPA1- and/or insulin-expressing progenitor cells that are
normally susceptible to KrasG12D oncogenic effect needs to be
amplified by tissue injury for the appearance of the phenotype.
Another possibility is that injury-induced regeneration or the
secretion of inflammatory cytokines leads to the proliferation of
stem cell/facultative stem cells that are most probably Pdx1+.
Upon the initiation of differentiation of such cells, a subset might
transiently express either proCPA1CreERT2 or RipCreERTM and,
thus, activate KrasG12D upon TM administration. However, our
results provide evidence that proCPA1- and insulin-expressing
cellscan formmPanINs, favoring the hypothesis that inflammation
and tissue injury facilitate PDAC development by promoting re-
programming of differentiated cells rather than by stem cell mobi-
lization. The mechanism through which such a reprogramming
event might occur requires further investigation. However, our
study and those of others suggest a role for the Notch signal-
ing pathway in this process. Caerulein-derived acinar-ductal.
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mez et al., 2004; Jensen et al., 2005; Siveke et al., 2008). We
also found Notch to be activated in mPanINs derived from caeru-
lein/TM RipCreERTM;LSL-KrasG12D mice. Reactivation of the
Notch signaling pathway, which is important for cell-fate deci-
sions and maintenance of undifferentiated stem/progenitor cells
during embryogenesis (Artavanis-Tsakonas et al., 1999), may be
a mechanism by which differentiated cells can revert to a stem/
progenitor fate or to convert to a cell type that is sensitive to
KrasG12D activity. It has been recently shown that Notch and
K-Ras reprogram acinar cells to mPanINs (De La O et al., 2008).
The precise mechanism of, and requirement for, interaction
between chronic pancreatitis, Notch, and K-Ras activation for
mPanIN formation from different pancreatic cells still needs to
be determined.
These data add to the increasing body of evidence pointing to
a remarkable plasticity of pancreatic adult differentiated cells (De
La O et al., 2008; Habbe et al., 2008; Shen et al., 2000; Zhou
et al., 2008) and question the existence of a pancreatic ‘‘stem
cell’’ as well as its relevance for PDAC. Our findings suggest
that KrasG12D regulates the differentiation status of pancreatic
epithelial progenitor/differentiated cells to a certain extent and
that in combination with nongenetic stress such as inflammation
this is further accelerated. More specifically, a multipotent Pdx1+
Insulin cell may exist in the adult pancreas. This cell type may
be the source of the endocrine cells within mPanINs and ductal
metaplasia observed in the TM-treated Pdx1CreERTM;LSL-
KrasG12D mice and the endocrine cells arising from the ductal
lining after pancreatic duct ligation (Xu et al., 2008). It is possible
that this cell type is activated only in certain settings such as
injury and neoplasia and may be particularly susceptible to
KrasG12D-induced proliferation and differentiation. It might also
be the source of the ductal structures located in the islets, if it
resides both in the ductal lining as well as the islets or if it
migrates to the islets under certain conditions. Alternatively,
these structures may arise from a differentiated cell, such as
the carbonic anhydrase II+ cell that gives rise to endocrine and
exocrine cells after birth and injury (Inada et al., 2008), upon
KrasG12D activation.
Our study reveals the involvement of different cell types in
PDAC initiation and provides a series of models to explore the
biology and treatment of PDAC. With the advances in the ability
to reprogram adult pancreatic cells in a controlled manner (Zhou
et al., 2008), we expect that a better understanding of the reprog-
ramming and transforming events attributed to KrasG12D activa-
tion in combination with chronic inflammation will lead to the
development of new therapeutic modalities to prevent PanIN
formation or to repair the diseased/damaged tissue.
EXPERIMENTAL PROCEDURES
Mouse Strains
All animal studies and procedures were approved by the Massachusetts Insti
tute of Technology Institutional Animal Care and Use Committee. Research
was conducted in compliance with the Animal Welfare Act Regulations and
other Federal statutes relating to animals and experiments involving animals
and adheres to the principles set forth in the Guide for Care and Use of Labo
ratory Animals, National Research Council, 1996. The LSL KrasG12D strain
(Jackson et al., 2001) was crossed to the following strains: Pdx1CreERTM
(Gu et al., 2002), proCPA1CreERT2 (Zhou et al., 2007), RipCreERTMC(Dor et al., 2004), Trp53flox (Jonkers et al., 2001), and Ink4A/Arfflox (Aguirre
et al., 2003). Primers used for genotyping by PCR are listed in Table S8 and
details of reactions are available upon request. Cre strains were crossed to
R26 LSL LacZ mice (Jackson Laboratories) to determine Cre expression
patterns.
Histopathology, Immunohistochemistry, and Immunofluorescence
Histopathologic analysis of pancreata was carried out by two pathologists
(G.C.C. and E.L.S.). mPanIN lesions and PDAC were graded according to
consensus criteria for mouse models of pancreatic cancer (Hruban et al.,
2006). We carried out IHC and IF analyses according to manufacturers’ recom
mendations, typically with a modified citric acid unmasking protocol followed
by standard detection with 3,3 diaminobenzidine with a kit from Vector Labo
ratories. In some cases, secondary antibodies were conjugated to AlexaFluor
594 (Invitrogen) and nuclei were counterstained with 4,6 diamidino 2 phenyl
indole. We used the following primary antibodies: insulin (Zymed), glucagon
(Abcam), PYY (RDI), Pdx1 (gift of C.V. Wright), CPA1 (Chemicon), and b galac
tosidase (AbD Serotec). IF staining was performed as described previously
(Jackson et al., 2001). Triple color microscopy and imaging were performed
with a Nikon Eclipse E600 and a Spot cooled CCD camera and software.
Images were processed with Adobe Photoshop.
b-Galactosidase Histochemistry
Pancreata were dissected and fixed in 4% PFA, incubated in 0.5 M Sucrose,
and frozen in OCT. b galactosidase activity was assayed as describe previ
ously (Paratore et al., 2002).
Tamoxifen Treatment
Mice were treated with TM (Sigma) by intraperitoneal injections (i.p.) of 9 mg/
40 g body weight in corn oil, one every other day for a total of three injections.
For oral delivery, TM was dissolved in a 0.5% CMC, 0.4% Tween 80, and 0.9%
NaCl solution.
Caerulein Treatment
Mice were i.p. injected with 0.1 ml of a 50 mg/ml caerulein (Sigma) in saline
solution five times per week.
Pancreata Size Measurement
Pancreata areas were determined with Bioquant Image Analysis software in
manual measurement mode.
Molecular Analysis
For verification of Cre mediated recombination, DNA was prepared from wild
type tails and LCM mPanINs of caerulein/TM treated proCPA1CreERT2;LSL
KrasG12D and RipCreERTM;LSL KrasG12D mice. PCR was performed with
primers flanking the Lox Stop Lox cassette (sequences available in Table
S8 and on http://web.mit.edu/jacks lab/protocols table.html). Wild type
K ras, 2Lox, and 1Lox K rasG12D alleles were detected, yielding 620 bp,
510 bp, and 1100 bp products, respectively. LCM and DNA isolation were
performed with the Veritas Microdissection System and the PicoPure DNA
Extraction Kit from Molecular Devices, respectively.
SUPPLEMENTAL DATA
Supplemental Data include three figures and eight tables and can be found
with this article online at http://www.cell.com/cancer cell/supplemental/
S1535 6108(09)00338 9.
ACKNOWLEDGMENTS
We are grateful to D. Melton for gifts of the Pdx1CreERTM, proCPA1CreERT2,
and RipCreERTM strains and stimulating discussions. We thank A. Berns
(Netherlands Cancer Institute) for providing the Trp53flox mice; C. Wright for
the anti Pdx1 antibody; S. Hoersch for statistical analysis; and N. Bardeesy
for critical reading of the manuscript. T.J. is a Howard Hughes Medical Institute
Investigator and a Daniel K. Ludwig Scholar. S.Y.G.F. is an Anna Fuller fund of
New Haven Fellow. R.A.D. is an American Cancer Society Research Professor.
This work was supported by grant 1 PO1 CA117969 01 from the Nationalancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier Inc. 387
Cancer Cell
K-Ras-Induced Tumorigenesis in Adult PancreasInstitutes of Health (NIH) and in part by Cancer Center Support (core) grant
P30 CA14051 from the National Cancer Institute (NCI). The content is solely
the responsibility of the authors and does not necessarily represent the official
views of the NCI or the NIH.
Received: September 23, 2008
Revised: July 14, 2009
Accepted: September 4, 2009
Published: November 2, 2009
REFERENCES
Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A., Horner, J.,
Redston, M.S., and DePinho, R.A. (2003). Activated Kras and Ink4a/Arf defi
ciency cooperate to produce metastatic pancreatic ductal adenocarcinoma.
Genes Dev. 17, 3112 3126.
Artavanis Tsakonas, S., Rand, M.D., and Lake, R.J. (1999). Notch signaling:
Cell fate control and signal integration in development. Science 284, 770 776.
Bardeesy, N., and DePinho, R.A. (2002). Pancreatic cancer biology and
genetics. Nat. Rev. Cancer 2, 897 909.
Bardeesy, N., and Sharpless, N.E. (2006). RAS unplugged: negative feedback
and oncogene induced senescence. Cancer Cell 10, 451 453.
Berman, D.M., Karhadkar, S.S., Maitra, A., Montes De Oca, R., Gerstenblith,
M.R., Briggs, K., Parker, A.R., Shimada, Y., Eshleman, J.R., Watkins, D.N.,
and Beachy, P.A. (2003). Widespread requirement for Hedgehog ligand stim
ulation in growth of digestive tract tumours. Nature 425, 846 851.
Carriere, C., Seeley, E.S., Goetze, T., Longnecker, D.S., and Korc, M. (2007).
The Nestin progenitor lineage is the compartment of origin for pancreatic intra
epithelial neoplasia. Proc. Natl. Acad. Sci. USA 104, 4437 4442.
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A.J., Barradas, M.,
Benguria, A., Zaballos, A., Flores, J.M., Barbacid, M., et al. (2005). Tumour
biology: Senescence in premalignant tumours. Nature 436, 642.
Danielian, P.S., Muccino, D., Rowitch, D.H., Michael, S.K., and McMahon, A.P.
(1998). Modification of gene activity in mouse embryos in utero by a tamoxifen
inducible form of Cre recombinase. Curr. Biol. 8, 1323 1326.
De La O, J.P., Emerson, L.L., Goodman, J.L., Froebe, S.C., Illum, B.E., Curtis,
A.B., and Murtaugh, L.C. (2008). Notch and Kras reprogram pancreatic aci
nar cells to ductal intraepithelial neoplasia. Proc. Natl. Acad. Sci. USA 105,
18907 18912.
Dor, Y., Brown, J., Martinez, O.I., and Melton, D.A. (2004). Adult pancreatic
beta cells are formed by self duplication rather than stem cell differentiation.
Nature 429, 41 46.
Gomez, G., Englander, E.W., Wang, G., and Greeley, G.H., Jr. (2004).
Increased expression of hypoxia inducible factor 1alpha, p48, and the Notch
signaling cascade during acute pancreatitis in mice. Pancreas 28, 58 64.
Grippo, P.J., Nowlin, P.S., Demeure, M.J., Longnecker, D.S., and Sandgren,
E.P. (2003). Preinvasive pancreatic neoplasia of ductal phenotype induced
by acinar cell targeting of mutant Kras in transgenic mice. Cancer Res. 63,
2016 2019.
Gu, G., Dubauskaite, J., and Melton, D.A. (2002). Direct evidence for the
pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from
duct progenitors. Development 129, 2447 2457.
Guerra, C., Schuhmacher, A.J., Canamero, M., Grippo, P.J., Verdaguer, L.,
Perez Gallego, L., Dubus, P., Sandgren, E.P., and Barbacid, M. (2007).
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarci
noma by K Ras oncogenes in adult mice. Cancer Cell 11, 291 302.
Habbe, N., Shi, G., Meguid, R.A., Fendrich, V., Esni, F., Chen, H., Feldmann,
G., Stoffers, D.A., Konieczny, S.F., Leach, S.D., and Maitra, A. (2008). Sponta
neous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by
acinar cell targeting of oncogenic Kras in adult mice. Proc. Natl. Acad. Sci.
USA 105, 18913 18918.
Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz,
M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. (2003). Preinva
sive and invasive ductal pancreatic cancer and its early detection in the mouse.
Cancer Cell 4, 437 450.388 Cancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier IncHoorens, A., Prenzel, K., Lemoine, N.R., and Kloppel, G. (1998). Undifferenti
ated carcinoma of the pancreas: analysis of intermediate filament profile and
Ki ras mutations provides evidence of a ductal origin. J. Pathol. 185, 53 60.
Hruban, R.H., Adsay, N.V., Albores Saavedra, J., Compton, C., Garrett, E.S.,
Goodman, S.N., Kern, S.E., Klimstra, D.S., Kloppel, G., Longnecker, D.S., et al.
(2001). Pancreatic intraepithelial neoplasia: a new nomenclature and classifi
cation system for pancreatic duct lesions. Am. J. Surg. Pathol. 25, 579 586.
Hruban, R.H., Adsay, N.V., Albores Saavedra, J., Anver, M.R., Biankin, A.V.,
Boivin, G.P., Furth, E.E., Furukawa, T., Klein, A., Klimstra, D.S., et al. (2006).
Pathology of genetically engineered mouse models of pancreatic exocrine
cancer: consensus report and recommendations. Cancer Res. 66, 95 106.
Inada, A., Nienaber, C., Katsuta, H., Fujitani, Y., Levine, J., Morita, R., Sharma,
A., and Bonner Weir, S. (2008). Carbonic anhydrase II positive pancreatic cells
are progenitors for both endocrine and exocrine pancreas after birth. Proc.
Natl. Acad. Sci. USA 105, 19915 19919.
Indra, A.K., Warot, X., Brocard, J., Bornert, J.M., Xiao, J.H., Chambon, P., and
Metzger, D. (1999). Temporally controlled site specific mutagenesis in the
basal layer of the epidermis: Comparison of the recombinase activity of the
tamoxifen inducible Cre ER(T) and Cre ER(T2) recombinases. Nucleic Acids
Res. 27, 4324 4327.
Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R.,
Jacks, T., and Tuveson, D.A. (2001). Analysis of lung tumor initiation and
progression using conditional expression of oncogenic K ras. Genes Dev.
15, 3243 3248.
Jaffee, E.M., Hruban, R.H., Canto, M., and Kern, S.E. (2002). Focus on
pancreas cancer. Cancer Cell 2, 25 28.
Jensen, J.N., Cameron, E., Garay, M.V., Starkey, T.W., Gianani, R., and Jen
sen, J. (2005). Recapitulation of elements of embryonic development in adult
mouse pancreatic regeneration. Gastroenterology 128, 728 741.
Johnson, S.M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A.,
Labourier, E., Reinert, K.L., Brown, D., and Slack, F.J. (2005). RAS is regulated
by the let 7 microRNA family. Cell 120, 635 647.
Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., Man
koo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008). Core signaling
pathways in human pancreatic cancers revealed by global genomic analyses.
Science 321, 1801 1806.
Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M.,
and Berns, A. (2001). Synergistic tumor suppressor activity of BRCA2 and p53
in a conditional mouse model for breast cancer. Nat. Genet. 29, 418 425.
Jonkers, Y.M., Ramaekers, F.C., and Speel, E.J. (2007). Molecular alterations
during insulinoma tumorigenesis. Biochim. Biophys. Acta 1775, 313 332.
Koizumi, M., Doi, R., Toyoda, E., Masui, T., Tulachan, S.S., Kawaguchi, Y., Fu
jimoto, K., Gittes, G.K., and Imamura, M. (2003). Increased PDX 1 expression
is associated with outcome in patients with pancreatic cancer. Surgery 134,
260 266.
Lee, Y.S., and Dutta, A. (2007). The tumor suppressor microRNA let 7
represses the HMGA2 oncogene. Genes Dev. 21, 1025 1030.
Li, D., Xie, K., Wolff, R., and Abbruzzese, J.L. (2004). Pancreatic cancer. Lancet
363, 1049 1057.
Mayr, C., Hemann, M.T., and Bartel, D.P. (2007). Disrupting the pairing
between let 7 and Hmga2 enhances oncogenic transformation. Science
315, 1576 1579.
Mills, S.E. (2007). Histology for Pathologists, Third Edition (Philadelphia: Lip
pincott Williams & Wilkins).
Miyamoto, Y., Maitra, A., Ghosh, B., Zechner, U., Argani, P., Iacobuzio Dona
hue, C.A., Sriuranpong, V., Iso, T., Meszoely, I.M., Wolfe, M.S., et al. (2003).
Notch mediates TGF alpha induced changes in epithelial differentiation during
pancreatic tumorigenesis. Cancer Cell 3, 565 576.
Paratore, C., Eichenberger, C., Suter, U., and Sommer, L. (2002). Sox10 hap
loinsufficiency affects maintenance of progenitor cells in a mouse model of
Hirschsprung disease. Hum. Mol. Genet. 11, 3075 3085.
Prasad, N.B., Biankin, A.V., Fukushima, N., Maitra, A., Dhara, S., Elkahloun,
A.G., Hruban, R.H., Goggins, M., and Leach, S.D. (2005). Gene expression.
Cancer Cell
K-Ras-Induced Tumorigenesis in Adult Pancreasprofiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog
signaling on pancreatic ductal epithelial cells. Cancer Res. 65, 1619–1626.
Rozenblum, E., Schutte, M., Goggins, M., Hahn, S.A., Panzer, S., Zahurak, M.,
Goodman, S.N., Sohn, T.A., Hruban, R.H., Yeo, C.J., and Kern, S.E. (1997).
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57,
1731–1734.
Seeburg, P.H., Colby, W.W., Capon, D.J., Goeddel, D.V., and Levinson, A.D.
(1984). Biological properties of human c-Ha-ras1 genes mutated at codon
12. Nature 312, 71–75.
Shen, C.N., Slack, J.M., and Tosh, D. (2000). Molecular basis of transdifferen-
tiation of pancreas to liver. Nat. Cell Biol. 2, 879–887.
Shields, J.M., Pruitt, K., McFall, A., Shaub, A., and Der, C.J. (2000). Under-
standing Ras: ‘it ain’t over ‘til it’s over’. Trends Cell Biol. 10, 147–154.
Siveke, J.T., Lubeseder-Martellato, C., Lee, M., Mazur, P.K., Nakhai, H.,
Radtke, F., and Schmid, R.M. (2008). Notch signaling is required for exocrine
regeneration after acute pancreatitis. Gastroenterology 134, 544–555.
Slack, J.M. (1995). Developmental biology of the pancreas. Development 121,
1569–1580.
Stanger, B.Z., Stiles, B., Lauwers, G.Y., Bardeesy, N., Mendoza, M., Wang, Y.,
Greenwood, A., Cheng, K.H., McLaughlin, M., Brown, D., et al. (2005). Pten
constrains centroacinar cell expansion and malignant transformation in the
pancreas. Cancer Cell 8, 185–195.
Stoffers, D.A., Heller, R.S., Miller, C.P., and Habener, J.F. (1999). Develop-
mental expression of the homeodomain protein IDX-1 in mice transgenic
for an IDX-1 promoter/lacZ transcriptional reporter. Endocrinology 140,
5374–5381.
Strobel, O., Dor, Y., Stirman, A., Trainor, A., Fernandez-del Castillo, C., War-
shaw, A.L., and Thayer, S.P. (2007). Beta cell transdifferentiation does not
contribute to preneoplastic/metaplastic ductal lesions of the pancreas by
genetic lineage tracing in vivo. Proc. Natl. Acad. Sci. USA 104, 4419–4424.
Swift, G.H., Liu, Y., Rose, S.D., Bischof, L.J., Steelman, S., Buchberg, A.M.,
Wright, C.V., and MacDonald, R.J. (1998). An endocrine-exocrine switch in
the activity of the pancreatic homeodomain protein PDX1 through formation
of a trimeric complex with PBX1b and MRG1 (MEIS2). Mol. Cell. Biol. 18,
5109–5120.
Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh,
H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., et al. (2004). ReducedCexpression of the let-7 microRNAs in human lung cancers in association
with shortened postoperative survival. Cancer Res. 64, 3753–3756.
Thayer, S.P., di Magliano, M.P., Heiser, P.W., Nielsen, C.M., Roberts, D.J.,
Lauwers, G.Y., Qi, Y.P., Gysin, S., Fernandez-del Castillo, C., Yajnik, V.,
et al. (2003). Hedgehog is an early and late mediator of pancreatic cancer
tumorigenesis. Nature 425, 851–856.
Tuveson, D.A., Zhu, L., Gopinathan, A., Willis, N.A., Kachatrian, L., Grochow,
R., Pin, C.L., Mitin, N.Y., Taparowsky, E.J., Gimotty, P.A., et al. (2006). Mist1-
KrasG12D knock-in mice develop mixed differentiation metastatic exo-
crine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res. 66,
242–247.
Wagner, M., Luhrs, H., Kloppel, G., Adler, G., and Schmid, R.M. (1998). Malig-
nant transformation of duct-like cells originating from acini in transforming
growth factor transgenic mice. Gastroenterology 115, 1254–1262.
Wang, L., Heidt, D.G., Lee, C.J., Yang, H., Logsdon, C.D., Zhang, L., Fearon,
E.R., Ljungman, M., and Simeone, D.M. (2009). Oncogenic function of ATDC in
pancreatic cancer through Wnt pathway activation and beta-catenin stabiliza-
tion. Cancer Cell 15, 207–219.
Wu, K.L., Gannon, M., Peshavaria, M., Offield, M.F., Henderson, E., Ray, M.,
Marks, A., Gamer, L.W., Wright, C.V., and Stein, R. (1997). Hepatocyte nuclear
factor 3beta is involved in pancreatic beta-cell-specific transcription of the
pdx-1 gene. Mol. Cell. Biol. 17, 6002–6013.
Xu, X., D’Hoker, J., Stange, G., Bonne, S., De Leu, N., Xiao, X., Van De Cas-
teele, M., Mellitzer, G., Ling, Z., Pipeleers, D., et al. (2008). Beta cells can be
generated from endogenous progenitors in injured adult mouse pancreas.
Cell 132, 197–207.
Yoshida, T., and Hanahan, D. (1994). Murine pancreatic ductal adenocarci-
noma produced by in vitro transduction of polyoma middle T oncogene into
the islets of Langerhans. Am. J. Pathol. 145, 671–684.
Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F.,
Lieberman, J., and Song, E. (2007). let-7 regulates self renewal and tumorige-
nicity of breast cancer cells. Cell 131, 1109–1123.
Zhou, Q., Law, A.C., Rajagopal, J., Anderson, W.J., Gray, P.A., and Melton,
D.A. (2007). A multipotent progenitor domain guides pancreatic organogen-
esis. Dev. Cell 13, 103–114.
Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., and Melton, D.A. (2008). In vivo
reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455,
627–632.ancer Cell 16, 379–389, November 3, 2009 ª2009 Elsevier Inc. 389
